protein

SF20/MYDGF Protein, Mouse

HY-P73303

2 μg;10 μg;50 μg;100 μg;500 μg;1 mg

48;125;320;510;1330;2150 USD

SF20/MYDGF Protein, Mouse

proteins

E. coli

2 μg;10 μg;50 μg;100 μg;500 μg;1 mg

48;125;320;510;1330;2150 USD

SF20/MYDGF protein promotes cardiac myocyte survival and adaptive angiogenesis after myocardial infarction (MI). It stimulates endothelial cell proliferation via MAPK1/3, STAT3, and CCND1 signaling, and inhibits cardiac myocyte apoptosis through PI3K/AKT signaling. Given its ability to enhance cardiac function and angiogenesis, SF20/MYDGF protein could be a valuable therapeutic target for improving outcomes in MI patients. SF20/MYDGF Protein, Mouse is the recombinant mouse-derived SF20/MYDGF, expressed by E. coli , with tag Free labeled tag. ,

Mouse

SF20/MYDGF protein is a bone marrow-derived monocyte and paracrine-acting protein that plays a crucial role in promoting cardiac myocyte survival and adaptive angiogenesis for cardiac protection and repair following myocardial infarction (MI). It exerts its effects by stimulating endothelial cell proliferation through a signaling pathway involving MAPK1/3, STAT3, and CCND1. Additionally, SF20/MYDGF protein inhibits cardiac myocyte apoptosis through a signaling pathway dependent on PI3K/AKT. This protein's ability to enhance cardiac function and promote angiogenesis makes it a potential therapeutic target for treating MI and improving cardiac outcomes.

Interleukin-25; IL-25; Interleukin-17E; IL-17E; SF20

Greater than 95% as determined by reducing SDS-PAGE.

Lyophilized from a 0.2 μm filter solution of PBS, pH 7.4.

Room temperature in continental US; may vary elsewhere.